The Most Expensive AI Mistake in Biotech Isn't a Hallucination, It's a Process Failure

AI failures in regulated biotech will stem not from model hallucinations but from treating AI as a standalone tool outside established governance frameworks, risking uncontrolled processes that regulators cannot audit. Life sciences must extend validation and change control to encompass the entire AI-assisted workflow, not just the model itself.

This Wire brief sits within Fusion42's coverage of Biotech and Healthtech Infrastructure.